ERBB2 and breast carcinoma: A phase 1b (NCT03429101) and other phase 2 studies were recently conducted in metastatic breast cancer patients, in monotherapy or association with T-DM1, both in HER-2-positive (NCT02659514; NCT02418689) and HER-2-mutant patients (NCT02544997), and preliminary data is still awaited (see Table 6).